Company: AIBT
Filing Date: 2025-04-11
Form Type: 10-K
Source: 0001096906-25-000487
Chunk: 1

Company: AIBOTICS, INC.
Filing Date: 2025-04-11
Form: 10-K
Item: Item 1
Chunk 1
---
have, Inc., and the former and current directors of 20/20 Global that provide for the 20/20 Global’s purchase of all of the outstanding stock of AIBotics, Inc. from Ehave, Inc. In May 2021, we changed our name to AIBotics Therapies Inc. Our trading symbol is TPIA. We have one subsidiary, AIBotics Therapies Inc., a Florida corporation. Our board of directors consists of Ben Kaplan and Mark Croskey.

Prior to its acquisition, AIBotics Therapies (Florida) entered into a supply agreement with Havn Life Sciences Inc. a Canadian corporation, a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products. The agreement calls for HAVN to supply AIBotics with naturally derived Psilocybin SPP in the form of an Active Pharmaceutical Ingredient (API) to be used in testing by universities, researchers and pharmaceutical companies seeking to develop treatments and therapies using Psilocybin. 

HAVN Life Sciences trades on the Canadian Securities Exchange (CSE) under the symbol HAVN.

Since the reverse merger on January 20, 2021 (the “Closing”), the Company has been leveraging its relationship with its parent company, Ehave, Inc. (“EHVVF”) to integrate the use of digital and data therapeutics to measure the effect of Psylicibin and related compounds on mental health. The Company has been negotiating with third parties to integrate EHVVF’s EEG brain cap technology to capture neurological data during the use of mental health therapies involving the use of Psylicibin and related compounds. The Company believes that the mental health benefits bestowed by these compounds are numerous, particularly to combat depression and addiction, and is aligning itself with the evolving legal and policy landscape of mental health regulation.

2

References to “us,” “we,” “our,” and correlative terms refer to AIBotics, Inc. and our wholly owned subsidiary, AIBotics, Inc., a Florida corporation, through which we conducted our activities.

On February 3, 2025, Mycotopia Therapies, Inc. amended its articles of incorporation to change its name to Aibotics Inc., (the “Name Change”). 

Business Strategy and Market

In November 2020, Oregon became the first U.S. state to legalize Psilocybin. It has been estimated the psychedelic drugs market will grow 12.4% annually over the next seven years, reaching